Myriad Genetics Stock Today
| MYGN Stock | USD 16.27 0.01 0.06% |
Performance0 of 100
| Odds Of DistressLess than 10
|
Myriad Genetics is selling at 16.27 as of the 30th of November 2024; that is 0.06 percent decrease since the beginning of the trading day. The stock's open price was 16.28. Myriad Genetics has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Equity ratings for Myriad Genetics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 3rd of June 2024 and ending today, the 30th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 5th of October 1995 | Category Healthcare | Classification Health Care |
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company was founded in 1991 and is headquartered in Salt Lake City, Utah. Myriad Genetics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. The company has 91.04 M outstanding shares of which 3.69 M shares are now shorted by private and institutional investors with about 3.96 trading days to cover. More on Myriad Genetics
Moving against Myriad Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Myriad Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | Paul JD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP Small-Cap 600, NASDAQ Biotechnology, NASDAQ Composite, Dow Jones Biotechnology, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Diagnostics & Research, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsMyriad Genetics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Myriad Genetics' financial leverage. It provides some insight into what part of Myriad Genetics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Myriad Genetics (MYGN) is traded on NASDAQ Exchange in USA. It is located in 322 North 2200 West, Salt Lake City, UT, United States, 84116 and employs 2,700 people. Myriad Genetics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.48 B. Myriad Genetics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 91.04 M outstanding shares of which 3.69 M shares are now shorted by private and institutional investors with about 3.96 trading days to cover.
Myriad Genetics currently holds about 205.1 M in cash with (110.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.54.
Check Myriad Genetics Probability Of Bankruptcy
Ownership AllocationThe majority of Myriad Genetics outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Myriad Genetics to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Myriad Genetics. Please pay attention to any change in the institutional holdings of Myriad Genetics as this could imply that something significant has changed or is about to change at the company.
Check Myriad Ownership Details
Myriad Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Dimensional Fund Advisors, Inc. | 2024-09-30 | 2.4 M | |
| Sei Investments Co | 2024-06-30 | 2.4 M | |
| Geode Capital Management, Llc | 2024-09-30 | 2.2 M | |
| Nuveen Asset Management, Llc | 2024-06-30 | 1.4 M | |
| Glenview Capital Management Llc | 2024-09-30 | 1.3 M | |
| D. E. Shaw & Co Lp | 2024-09-30 | 1.2 M | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 1.1 M | |
| Point72 Asset Management, L.p. | 2024-09-30 | 1.1 M | |
| Northern Trust Corp | 2024-09-30 | 967.2 K | |
| Blackrock Inc | 2024-06-30 | 15.2 M | |
| Vanguard Group Inc | 2024-09-30 | 10.3 M |
Myriad Genetics Historical Income Statement
Myriad Stock Against Markets
Myriad Genetics Corporate Management
| Justin Hunter | Interim Secretary | Profile | |
| Nicole Lambert | Chief Officer | Profile | |
| Jennifer Fox | Chief Officer | Profile | |
| Clivetty Martinez | Chief Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Myriad Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Myriad Genetics. If investors know Myriad will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Myriad Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.28) | Revenue Per Share 9.205 | Quarterly Revenue Growth 0.112 | Return On Assets (0.05) | Return On Equity (0.16) |
The market value of Myriad Genetics is measured differently than its book value, which is the value of Myriad that is recorded on the company's balance sheet. Investors also form their own opinion of Myriad Genetics' value that differs from its market value or its book value, called intrinsic value, which is Myriad Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Myriad Genetics' market value can be influenced by many factors that don't directly affect Myriad Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Myriad Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Myriad Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Myriad Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.